Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
David R Lynch, Kim Schadt, Elizabeth Kichula, Shana McCormack & Kimberly Y Lin. (2021) Friedreich Ataxia: Multidisciplinary Clinical Care. Journal of Multidisciplinary Healthcare 14, pages 1645-1658.
Read now
Read now
Layne N Rodden & David R Lynch. (2021) Designing phase II clinical trials in Friedreich ataxia. Expert Opinion on Emerging Drugs 26:4, pages 415-423.
Read now
Read now
Shaila D Ghanekar, Wai Wai Miller, Colin J Meyer, Kevin J Fenelon, Alvin Lacdao & Theresa A Zesiewicz. (2019) Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone. Degenerative Neurological and Neuromuscular Disease 9, pages 103-107.
Read now
Read now
Alexandra Clay, Patrick Hearle, Kim Schadt & David R. Lynch. (2019) New developments in pharmacotherapy for Friedreich ataxia. Expert Opinion on Pharmacotherapy 20:15, pages 1855-1867.
Read now
Read now
Christian Rummey, Elizabeth Kichula & David R. Lynch. (2018) Clinical trial design for Friedreich ataxia - Where are we now and what do we need?. Expert Opinion on Orphan Drugs 6:3, pages 219-230.
Read now
Read now
Articles from other publishers (53)
Tslil Ast, Hong Wang, Eizo Marutani, Fumiaki Nagashima, Rajeev Malhotra, Fumito Ichinose & Vamsi K Mootha. (2023) Continuous, but not intermittent, regimens of hypoxia prevent and reverse ataxia in a murine model of Friedreich’s ataxia. Human Molecular Genetics 32:16, pages 2600-2610.
Crossref
Crossref
Gilles Naeije, Antonin Rovai, Virginie Destrebecq, Nicola Trotta & Xavier De Tiège. (2023) Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial. Movement Disorders 38:8, pages 1443-1450.
Crossref
Crossref
David R. Lynch, Katherine D. Mathews, Susan Perlman, Theresa Zesiewicz, Sub Subramony, Omid Omidvar, Adam P. Vogel, Ana Krtolica, Nadia Litterman, Lex van der Ploeg, Frederic Heerinckx, Peter Milner & Mark Midei. (2022) Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia. Journal of Neurology 270:3, pages 1615-1623.
Crossref
Crossref
Chi-Ying R. Lin & Sheng-Han Kuo. (2023) Ataxias: Hereditary, Acquired, and Reversible Etiologies. Seminars in Neurology 43:01, pages 048-064.
Crossref
Crossref
Jinjuan Yang, Xiaoxian Zhang, Meng Kou, Boon Xuan Lian, Zhixin Chiang, Jace Chen, Xiaoya Zhou, Ziyue Li, Jinqiu Zhang, Xiao Su & Qizhou Lian. (2023) Mitochondrial cardiomyopathy and emerging therapeutics. Translational Medicine of Aging 7, pages 98-108.
Crossref
Crossref
Dilip Waman Shingare, Kailas Kalicharan Moravkar, Jaywant Pawar & Chandrakantsing Vijaysing Pardeshi. 2023. Nanotechnology and Regenerative Medicine. Nanotechnology and Regenerative Medicine
455
475
.
William Motley, Vinay Chaudry & Thomas E. Lloyd. 2022. Neuromuscular Disorders. Neuromuscular Disorders
278
311
.
Antoni Matilla-Dueñas, Jon Infante, Carmen Serrano-Munuera, Yerko Ivánovic-Barbeito, Ramiro Alvarez & Ivelisse Sánchez. 2022. Handbook of the Cerebellum and Cerebellar Disorders. Handbook of the Cerebellum and Cerebellar Disorders
2667
2699
.
Winfried Ilg & Dagmar Timmann. 2022. Handbook of the Cerebellum and Cerebellar Disorders. Handbook of the Cerebellum and Cerebellar Disorders
2639
2666
.
Yutong Liu, Jing Cai, Jiaqi Shen, Weichen Dong, Li Xu, Maoxin Fang, Yishan Lin, Jiali Liu, Yibing Ding, Tong Qiao & Kuanyu Li. (2022) SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression. Human Molecular Genetics 31:2, pages 176-188.
Crossref
Crossref
Abraham J. Paredes-Fuentes, Sergi Cesar, Raquel Montero, Cristina Latre, Jordi Genovès, Loreto Martorell, Daniel Cuadras, Helena Colom, Mercè Pineda, Maria del Mar O’Callaghan, Georgia Sarquella-Brugada, Alejandra Darling & Rafael Artuch. (2021) Plasma idebenone monitoring in Friedreich’s ataxia patients during a long-term follow-up. Biomedicine & Pharmacotherapy 143, pages 112143.
Crossref
Crossref
Serena Viventi, Stefano Frausin, Sara E. Howden, Shiang Y. Lim, Rocio K. Finol-Urdaneta, Jeffrey R. McArthur, Kwaku Dad Abu-Bonsrah, Wayne Ng, Jason Ivanusic, Lachlan Thompson & Mirella Dottori. (2021) In Vivo Survival and Differentiation of Friedreich Ataxia iPSC-Derived Sensory Neurons Transplanted in the Adult Dorsal Root Ganglia. Stem Cells Translational Medicine 10:8, pages 1157-1169.
Crossref
Crossref
Masha G Savelieff & Eva L Feldman. (2021) Lessons for clinical trial design in Friedreich's ataxia. The Lancet Neurology 20:5, pages 330-332.
Crossref
Crossref
David R Lynch & Joseph Johnson. (2021) Omaveloxolone: potential new agent for Friedreich ataxia. Neurodegenerative Disease Management 11:2, pages 91-98.
Crossref
Crossref
Bernice Frempong, Robert B. Wilson, Kimberly Schadt & David R. Lynch. (2021) The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia. Frontiers in Neuroscience 15.
Crossref
Crossref
Federico V. Pallardó, Giovanni Pagano, Laura R. Rodríguez, Pilar Gonzalez-Cabo, Alex Lyakhovich & Marco Trifuoggi. (2021) Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Translational Research 229, pages 135-141.
Crossref
Crossref
David R. Lynch, Melanie P. Chin, Martin B. Delatycki, S. H. Subramony, Manuela Corti, J. Chad Hoyle, Sylvia Boesch, Wolfgang Nachbauer, Caterina Mariotti, Katherine D. Mathews, Paola Giunti, George Wilmot, Theresa Zesiewicz, Susan Perlman, Angie Goldsberry, Megan O'Grady & Colin J. Meyer. (2020)
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (
MOXIe
Study)
. Annals of Neurology 89:2, pages 212-225.
Crossref
Crossref
Marta Seco-Cervera, Pilar González-Cabo, Federico Pallardó, Carlos Romá-Mateo & José García-Giménez. (2020) Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia. Antioxidants 9:12, pages 1257.
Crossref
Crossref
Frances M. Smith & Daniel J. Kosman. (2020) Molecular Defects in Friedreich’s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Antonella Bizzoca, Martina Caracciolo, Patrizia Corsi, Thea Magrone, Emilio Jirillo & Gianfranco Gennarini. (2020) Molecular and Cellular Substrates for the Friedreich Ataxia. Significance of Contactin Expression and of Antioxidant Administration. Molecules 25:18, pages 4085.
Crossref
Crossref
Parisa Afsharian, Rachel Nolan-Kenney, Abigail E. Lynch, Laura J. Balcer & David R. Lynch. (2020) Correlation of Visual Quality of Life With Clinical and Visual Status in Friedreich Ataxia. Journal of Neuro-Ophthalmology 40:2, pages 213-217.
Crossref
Crossref
Julia O. Misiorek, Anna M. Schreiber, Martyna O. Urbanek-Trzeciak, Magdalena Jazurek-Ciesiołka, Lauren A. Hauser, David R. Lynch, Jill S. Napierala & Marek Napierala. (2020) A Comprehensive Transcriptome Analysis Identifies FXN and BDNF as Novel Targets of miRNAs in Friedreich’s Ataxia Patients. Molecular Neurobiology 57:6, pages 2639-2653.
Crossref
Crossref
Matthew P. Dale, Tessa Moses, Emily J. Johnston & Susan J. Rosser. (2020) A systematic comparison of triterpenoid biosynthetic enzymes for the production of oleanolic acid in Saccharomyces cerevisiae. PLOS ONE 15:5, pages e0231980.
Crossref
Crossref
Henan Zhao, Bevan M. Lewellen, Rebecca J. Wilson, Di Cui, Joshua C. Drake, Mei Zhang & Zhen Yan. (2020) Long-term voluntary running prevents the onset of symptomatic Friedreich’s ataxia in mice. Scientific Reports 10:1.
Crossref
Crossref
Javier Pérez-Flores, Atteneri Hernández-Torres, Fernando Montón & Antonieta Nieto. (2019) Health-related quality of life and depressive symptoms in Friedreich ataxia. Quality of Life Research 29:2, pages 413-420.
Crossref
Crossref
Piergiorgio La Rosa, Enrico Silvio Bertini & Fiorella Piemonte. (2020) The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich’s Ataxia. International Journal of Molecular Sciences 21:3, pages 916.
Crossref
Crossref
Antoni Matilla-Dueñas, Jon Infante, Carmen Serrano-Munuera, Yerko Ivánovic-Barbeito, Ramiro Alvarez & Ivelisse Sánchez. 2020. Handbook of the Cerebellum and Cerebellar Disorders. Handbook of the Cerebellum and Cerebellar Disorders
1
33
.
Winfried Ilg & Dagmar Timmann. 2020. Handbook of the Cerebellum and Cerebellar Disorders. Handbook of the Cerebellum and Cerebellar Disorders
1
28
.
Carlotta Bon, Riccardo Luffarelli, Roberta Russo, Silvia Fortuni, Bianca Pierattini, Chiara Santulli, Cristina Fimiani, Francesca Persichetti, Diego Cotella, Antonello Mallamaci, Claudio Santoro, Piero Carninci, Stefano Espinoza, Roberto Testi, Silvia Zucchelli, Ivano Condò & Stefano Gustincich. (2019) SINEUP non-coding RNAs rescue defective frataxin expression and activity in a cellular model of Friedreich's Ataxia. Nucleic Acids Research 47:20, pages 10728-10743.
Crossref
Crossref
Liwei Weng, Qingqing Wang, Sixiang Yu, Xiaolu Yang, David R. Lynch, Clementina Mesaros & Ian A. Blair. (2019) Evaluation of antibodies for western blot analysis of frataxin protein isoforms. Journal of Immunological Methods 474, pages 112629.
Crossref
Crossref
Sara Petrillo, Jessica D’Amico, Piergiorgio La Rosa, Enrico Silvio Bertini & Fiorella Piemonte. (2019) Targeting NRF2 for the Treatment of Friedreich’s Ataxia: A Comparison among Drugs. International Journal of Molecular Sciences 20:20, pages 5211.
Crossref
Crossref
N. N. Koberskaya. (2019) The role of mitochondrial dysfunction in Alzheimer’s disease. Medical Council:12, pages 34-40.
Crossref
Crossref
Ian A Blair, Jennifer Farmer, Steven Hersch, Jane Larkindale, David R Lynch, Jill Napierala, Marek Napierala, R Mark Payne & Sub H Subramony. (2019) The current state of biomarker research for Friedreich’s ataxia: a report from the 2018 FARA biomarker meeting. Future Science OA 5:6.
Crossref
Crossref
Mittal Jasoliya, Francesco Sacca, Sunil Sahdeo, Frederic Chedin, Chiara Pane, Vincenzo Brescia Morra, Alessandro Filla, Mark Pook & Gino Cortopassi. (2019) Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia. PLOS ONE 14:6, pages e0217776.
Crossref
Crossref
Yi Na Dong, Emily McMillan, Elisia M Clark, Hong Lin & David R Lynch. (2019) GRP75 overexpression rescues frataxin deficiency and mitochondrial phenotypes in Friedreich ataxia cellular models. Human Molecular Genetics 28:10, pages 1594-1607.
Crossref
Crossref
Brahim Belbellaa, Laurence Reutenauer, Laurent Monassier & Hélène Puccio. (2019) Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms. Human Molecular Genetics 28:8, pages 1274-1285.
Crossref
Crossref
Siyuan Zhang, Marek Napierala & Jill S. Napierala. (2019) Therapeutic Prospects for Friedreich’s Ataxia. Trends in Pharmacological Sciences 40:4, pages 229-233.
Crossref
Crossref
Rula Zain & C. I. Edvard Smith. (2019) Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. Neurotherapeutics 16:2, pages 248-262.
Crossref
Crossref
Belén Mollá, Diana C. Muñoz-Lasso, Pablo Calap, Angel Fernandez-Vilata, María de la Iglesia-Vaya, Federico V. Pallardó, Maria Dolores Moltó, Francesc Palau & Pilar Gonzalez-Cabo. (2019) Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich’s Ataxia Mouse Model. Neurotherapeutics 16:2, pages 432-449.
Crossref
Crossref
E. V. Kostenko & L. V. Petrova. (2019) Pathophysiological features of chronic cerebrovascular diseases and possibilities of complex neuroprotective therapy. Medical Council:1, pages 24-30.
Crossref
Crossref
David R. Lynch, Kimberly Schadt & Elizabeth Kichula. (2019) Etravirine in Friedreich's ataxia: Lessons from HIV?. Movement Disorders 34:3, pages 305-306.
Crossref
Crossref
Giulia Alfedi, Riccardo Luffarelli, Ivano Condò, Giorgia Pedini, Liliana Mannucci, Damiano S. Massaro, Monica Benini, Nicola Toschi, Giorgia Alaimo, Luca Panarello, Laura Pacini, Silvia Fortuni, Dario Serio, Florence Malisan, Roberto Testi & Alessandra Rufini. (2019) Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia. Movement Disorders 34:3, pages 323-334.
Crossref
Crossref
David R. Lynch, Lauren Hauser, Ashley McCormick, McKenzie Wells, Yi Na Dong, Shana McCormack, Kim Schadt, Susan Perlman, Sub H. Subramony, Katherine D. Mathews, Alicia Brocht, Julie Ball, Renee Perdok, Amy Grahn, Tom Vescio, Jeffrey W. Sherman & Jennifer M. Farmer. (2019)
Randomized, double‐blind, placebo‐controlled study of interferon‐
γ
1b in Friedreich Ataxia
. Annals of Clinical and Translational Neurology 6:3, pages 546-553.
Crossref
Crossref
José Vicente Llorens, Sirena Soriano, Pablo Calap-Quintana, Pilar Gonzalez-Cabo & María Dolores Moltó. (2019) The Role of Iron in Friedreich’s Ataxia: Insights From Studies in Human Tissues and Cellular and Animal Models. Frontiers in Neuroscience 13.
Crossref
Crossref
Diane M. Ward & Suzanne M. Cloonan. (2019) Mitochondrial Iron in Human Health and Disease. Annual Review of Physiology 81:1, pages 453-482.
Crossref
Crossref
Jeremy S. Wetzel, Nathan Hardcastle, Muhibullah S. Tora, Thais Federici, Stephen Frey, Jennifer Novek, Tony Arulanandam, Mark Johnson, Randy Pielemeier & Nicholas M. Boulis. (2019) Frameless Stereotactic Targeting of the Cerebellar Dentate Nucleus in Nonhuman Primates: Translatable Model for the Surgical Delivery of Gene Therapy. Stereotactic and Functional Neurosurgery 97:5-6, pages 293-302.
Crossref
Crossref
Stephanie Salabarria, Barry J. Byrne, Cristina Liberati & Manuela Corti. 2019. Muscle Gene Therapy. Muscle Gene Therapy
579
596
.
Véronique Monnier, Jose Llorens & Juan Navarro. (2018) Impact of Drosophila Models in the Study and Treatment of Friedreich’s Ataxia. International Journal of Molecular Sciences 19:7, pages 1989.
Crossref
Crossref
A. V. Vanlander & R. Van Coster. (2018) Clinical and genetic aspects of defects in the mitochondrial iron–sulfur cluster synthesis pathway. JBIC Journal of Biological Inorganic Chemistry 23:4, pages 495-506.
Crossref
Crossref
Geneieve Tai, Louise A. Corben, Eppie M. Yiu, Sarah C. Milne & Martin B. Delatycki. (2018) Progress in the treatment of Friedreich ataxia. Neurologia i Neurochirurgia Polska 52:2, pages 129-139.
Crossref
Crossref
QingQing Wang, Lili Guo, Cassandra J. Strawser, Lauren A. Hauser, Wei-Ting Hwang, Nathaniel W. Snyder, David R. Lynch, Clementina Mesaros & Ian A. Blair. (2018) Low apolipoprotein A-I levels in Friedreich’s ataxia and in frataxin-deficient cells: Implications for therapy. PLOS ONE 13:2, pages e0192779.
Crossref
Crossref
Lili Guo, Qingqing Wang, Liwei Weng, Lauren A. Hauser, Cassandra J. Strawser, Agostinho G. Rocha, Andrew Dancis, Clementina Mesaros, David R. Lynch & Ian A. Blair. (2018) Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich’s Ataxia. Analytical Chemistry 90:3, pages 2216-2223.
Crossref
Crossref
Lucia Montenegro, Rita Turnaturi, Carmela Parenti & Lorella Pasquinucci. (2018) Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy. Nanomaterials 8:2, pages 87.
Crossref
Crossref